Answers are grounded in this paper and cite their sources.
Neutrophilic asthma represents a severe, often corticosteroid-insensitive asthma subtype with an unmet clinical need for new therapeutic targets. This study aimed to identify key molecular mediators and regulatory pathways involved in neutrophilic airway inflammation through unbiased bioinformatic analysis of public human asthma transcriptomic datasets. Among the identified hub genes, C-X-C motif chemokine ligand 2 (CXCL2), a critical driver of neutrophil recruitment and pulmonary inflammation, was prioritized for mechanistic follow-up. We combined HDM-induced murine asthma models, dual-luciferase reporter assays and ChIP-qPCR to characterize the transcriptional regulation of CXCL2. Our results demonstrate that transcription factor Nrf2 directly binds the CXCL2 promoter and suppresses CXCL2 transcription. Genetic deletion of Nrf2 exacerbates neutrophil infiltration, airway inflammation and epithelial barrier disruption accompanied by increased CXCL2 expression, whereas pharmacological Nrf2 activation by MOTS-c downregulates CXCL2 and alleviates neutrophilic airway inflammation. Collectively, this work identifies the Nrf2/CXCL2 axis as a candidate regulatory pathway in experimental neutrophilic asthma, providing a potential target for further translational investigation.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: